1101120-37-9

Basic information

• Product Name: H-pyrazolo[1,5-a]pyridin-5-aMine
• Synonyms: H-pyrazolo[1,5-a]pyridin-5-aMine;Pyrazolo[1,5-a]pyridin-5-aMine
• CAS NO: 1101120-37-9
• Molecular Formula: C₇H₇N₃
• Molecular Weight: 133.15058
• EINECS: -0
• Mol File: 1101120-37-9.mol

Chemical Properties

• Appearance: /
• Density: 1.32±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 4.53±0.30(Predicted)
• CAS DataBase Reference: H-pyrazolo[1,5-a]pyridin-5-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: H-pyrazolo[1,5-a]pyridin-5-aMine(1101120-37-9)
• EPA Substance Registry System: H-pyrazolo[1,5-a]pyridin-5-aMine(1101120-37-9)

Safety Data

• Hazardous Substances Data: 1101120-37-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
H-pyrazolo[1,5-a]pyridin-5-aMine is used as an antidiabetic medication for managing blood sugar levels in patients with type 2 diabetes. It functions by increasing insulin secretion from the pancreas and improving the sensitivity of peripheral tissues to insulin, thereby helping to control diabetes.
Used in Research and Development:
H-pyrazolo[1,5-a]pyridin-5-aMine is utilized in scientific research for exploring its potential anti-cancer and anti-inflammatory properties. This research aims to expand the therapeutic applications of glimepiride beyond diabetes management and contribute to the development of new treatments for various diseases.

Upstream product

• 98400-69-2 N-(4-pyridyl) t-butyl carbamate 
• 1101120-33-5 5-[(tert-butoxycarbonyl)amino]pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester 

Downstream Products

• 1101120-47-1 5-chloropyrazolo[1,5-a]pyridine 
• 1101120-49-3 5-chloropyrazolo[1,5-a]pyridine-3-carbaldehyde 
• 1101118-17-5 N'-((5-chloropyrazolo[1,5-a]pyridin-3-yl)methylene)-N,2-dimethyl-5-nitrobenzenesulfonohydrazide 
• 1610612-89-9 pyrazolo[1,5-a]pyridine-5-sulfonyl chloride 

Relevant articles and documents

Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure

1,4-Disubstituted aromatic piperazines are privileged structural motifs recognized by aminergic G protein-coupled receptors. Connection of a lipophilic moiety to the arylpiperazine core by an appropriate linker represents a promising concept to increase binding affinity and to fine-tune functional properties. In particular, incorporation of a pyrazolo[1,5-a]pyridine heterocyclic appendage led to a series of high-affinity dopamine receptor partial agonists. Comprehensive pharmacological characterization involving BRET biosensors, binding studies, electrophysiology, and complementation-based assays revealed compounds favoring activation of G proteins (preferably Go) over β-arrestin recruitment at dopamine D2 receptors. The feasibility to design G protein-biased partial agonists as putative novel therapeutics was demonstrated for the representative 2-methoxyphenylpiperazine 16c, which unequivocally displayed antipsychotic activity in vivo. Moreover, combination of the pyrazolo[1,5-a]pyridine appendage with a 5-hydroxy-N-propyl-2-aminotetraline unit led to balanced or G protein-biased dopaminergic ligands depending on the stereochemistry of the headgroup, illustrating the complex structure-functional selectivity relationships at dopamine D2 receptors.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors

We have made a novel series of pyrazolo[1,5-a]pyridines as PI3 kinase inhibitors, and demonstrated their selectivity for the p110α isoform over the other Class Ia PI3 kinases. We investigated the SAR around the pyrazolo[1,5-a]pyridine ring system, and found compound 5x to be a particularly potent example (p110α IC50 0.9 nM). This compound inhibits cell proliferation and phosphorylation of Akt/PKB, a downstream marker of PI3 kinase activity, and showed in vivo activity in an HCT-116 human xenograft model.

PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY

Pyrazolo[1,5-a]pyridines are described, including methods for their preparation, and their use as agents or drugs for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.